Enanta Pharmaceuticals(ENTA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 • Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 • Operations Supported by Cash and Marketable Securities Totaling $272.6 Million at June 30, 2024, as well as Continuing Retai ...